With an estimated 30% of AMR-related deaths a result of
drug-resistant TB globally, the choice of drugs used for
treatment of TB disease is of the utmost importance.
However, many cases of TB disease are treated without a
complete knowledge of the resistance profile of the
underlying bacteria, due to a lack of availability of diagnostic
tests.

The aim of this project will be to improve the decision-making
around such empiric therapy, by using mathematical
modelling and quantitative methods to balance and assess
the factors contributing to the decision-making process. The
intention will be to inform development of treatment
guidelines, to ensure that treatment decisions are based on a
comprehensive consideration of evidence.

The outputs from this project will translate directly into clinical
care impact and can support optimised antibiotic usage for
TB and other important pathogens globally.

For more details see https://mrc-lid.lshtm.ac.uk/files/2021/11/McQuaid-Knight.pdf, or get in touch